engleski

ANTAGONIST (IL-1RA) ON CORNEAL ALLOGRAFT SURVIVAL IN IMMUNIZED HOSTS – EXPERIMENTAL MODEL

Purpose. Topical interleukin-1 receptor antagonist (IL-1ra) promotes corneal allograft survival in naive hosts. The purpose of this experiment was to test whether IL-1ra could likewise promote transplant survival in presensitized host. Methods. Orthotopic corneal grafts were performed into immunized (n=65) and naive (n=40) BALB/c recipients from fully disparate (C57Bl/6) or minor H-only disparate (B10.D2) mice. Allograft recipients were randomized to recieve treatment with IL-1ra or vehicle only. Results. Immunization to both MHC and minor H alloantigens was associated with accelerated graft rejection. IL-1ra treatment had no significant impact on overall graft longevity or the early incidence of graft rejection in pre-immunized recipeints of fully-disparate corneal allograft (p=0.25). Similarly, although rejection of corneal allograft in hosts immunized to minor H allontigens occured more slowly in mice treated with IL-1ra than in controls (p=0.04), overall graft survival at 8 weeks was comparable (p=0.07) among the two groups. Conclusion. Il-1ra is not effective in preventing corneal graft rejection in immunized hosts. These data confirm that the role of IL-1ra is primarily limited to downmodulating the afferent, not expression, arm of alloimmunity.

IL-1ra; keratoplasty

nije evidentirano